Loading…
Loading…
EQUITY / NASDAQ · XNCM
Processa Pharmaceuticals Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.61 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 1.61 USD · Volume 15,134
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -2,336,138 USD | -3,950,783 USD | — |
| Net income | -3,265,494 USD | -3,933,918 USD | — |
| Cash and cash equivalents | 196,325 USD | — | — |
| Total liabilities | 2,386,903 USD | — | — |
| Total equity | -317,341 USD | 6,107,208 USD | -105.20% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 196,325 USD | — | — | 5,536,955 USD | 5,536,955 USD | 6,308,420 USD | — | — |
| Net incomeIncome statement | -3,265,494 USD | -6,642,673 USD | -3,377,179 USD | — | -13,563,834 USD | -3,436,573 USD | -10,204,896 USD | -3,933,918 USD |
| Operating profitIncome statement | -2,336,138 USD | -5,667,352 USD | — | — | -13,988,505 USD | -3,488,843 USD | -10,286,616 USD | -3,950,783 USD |
| Total assetsBalance sheet | 2,069,562 USD | — | — | 7,813,567 USD | 7,813,567 USD | 7,584,576 USD | — | — |
| Total equityBalance sheet | -317,341 USD | — | 2,540,881 USD | 5,577,314 USD | 5,577,314 USD | 5,833,598 USD | — | 6,107,208 USD |
| Total liabilitiesBalance sheet | 2,386,903 USD | — | — | 2,236,253 USD | 2,236,253 USD | 1,750,978 USD | — | — |
| Financing cash flowCash flow statement | — | 559,950 USD | — | — | 16,580,825 USD | — | 13,601,712 USD | — |
| Investing cash flowCash flow statement | — | -314,000 USD | — | — | -850,000 USD | — | — | — |
| Operating cash flowCash flow statement | — | -5,586,580 USD | — | — | -11,385,195 USD | — | -8,484,617 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/18/2026 | Open report ↗ Published: 11/06/2025 | Open report ↗ Published: 11/06/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.